| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 4 | 2011 | 138 | 1.150 |
Why?
|
| Osteopetrosis | 1 | 2022 | 8 | 0.860 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2022 | 245 | 0.810 |
Why?
|
| Receptors, Thromboxane | 3 | 2011 | 122 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-ets | 8 | 2011 | 79 | 0.700 |
Why?
|
| Cell Movement | 9 | 2014 | 630 | 0.690 |
Why?
|
| Protein Isoforms | 2 | 2011 | 246 | 0.660 |
Why?
|
| Thromboxane-A Synthase | 2 | 2011 | 24 | 0.660 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2011 | 756 | 0.490 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2014 | 48 | 0.490 |
Why?
|
| Urologic Neoplasms | 1 | 2014 | 14 | 0.490 |
Why?
|
| Graft Rejection | 8 | 2018 | 458 | 0.480 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 6 | 2010 | 106 | 0.470 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 94 | 0.470 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 194 | 0.440 |
Why?
|
| Histocompatibility Testing | 3 | 2020 | 38 | 0.430 |
Why?
|
| Kidney Transplantation | 6 | 2020 | 839 | 0.420 |
Why?
|
| Arrestins | 1 | 2013 | 92 | 0.410 |
Why?
|
| Thromboxane B2 | 1 | 2011 | 108 | 0.390 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 122 | 0.340 |
Why?
|
| HLA Antigens | 3 | 2016 | 82 | 0.330 |
Why?
|
| RNA, Messenger | 4 | 2009 | 1664 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 710 | 0.330 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 508 | 0.300 |
Why?
|
| Tissue and Organ Procurement | 4 | 2020 | 164 | 0.290 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 299 | 0.290 |
Why?
|
| Signal Transduction | 4 | 2014 | 2689 | 0.290 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 114 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2014 | 1851 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2005 | 411 | 0.250 |
Why?
|
| Neoplasm Proteins | 2 | 2006 | 307 | 0.240 |
Why?
|
| Neoplasms | 3 | 2013 | 1667 | 0.240 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 1536 | 0.230 |
Why?
|
| Graft Survival | 3 | 2016 | 465 | 0.220 |
Why?
|
| Histocompatibility | 2 | 2016 | 17 | 0.220 |
Why?
|
| Isoantibodies | 2 | 2016 | 35 | 0.220 |
Why?
|
| Humans | 28 | 2022 | 68618 | 0.220 |
Why?
|
| In Vitro Techniques | 1 | 2022 | 765 | 0.190 |
Why?
|
| Intravitreal Injections | 1 | 2021 | 16 | 0.190 |
Why?
|
| Osteogenesis | 1 | 2022 | 152 | 0.190 |
Why?
|
| Heart Transplantation | 2 | 2014 | 328 | 0.190 |
Why?
|
| Macular Edema | 1 | 2021 | 21 | 0.190 |
Why?
|
| Cell Differentiation | 3 | 2010 | 1034 | 0.190 |
Why?
|
| Bevacizumab | 1 | 2021 | 34 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 64 | 0.180 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 562 | 0.180 |
Why?
|
| DNA Primers | 3 | 2010 | 302 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 331 | 0.180 |
Why?
|
| Diabetic Retinopathy | 1 | 2021 | 110 | 0.180 |
Why?
|
| Base Sequence | 4 | 2010 | 1015 | 0.180 |
Why?
|
| Trans-Activators | 4 | 2004 | 237 | 0.170 |
Why?
|
| Donor Selection | 1 | 2020 | 29 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2011 | 369 | 0.170 |
Why?
|
| Melanoma | 1 | 2023 | 335 | 0.170 |
Why?
|
| Plasma Exchange | 1 | 2018 | 18 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2013 | 1174 | 0.160 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2018 | 80 | 0.160 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2016 | 42 | 0.150 |
Why?
|
| Antilymphocyte Serum | 2 | 2016 | 52 | 0.150 |
Why?
|
| Antibodies | 1 | 2018 | 241 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2009 | 268 | 0.150 |
Why?
|
| Phenotype | 5 | 2013 | 947 | 0.140 |
Why?
|
| DNA-Binding Proteins | 4 | 2004 | 700 | 0.140 |
Why?
|
| Animals | 12 | 2023 | 20881 | 0.140 |
Why?
|
| Mice | 9 | 2023 | 8474 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2005 | 753 | 0.140 |
Why?
|
| Patient Selection | 1 | 2020 | 592 | 0.130 |
Why?
|
| Epitopes | 1 | 2016 | 146 | 0.130 |
Why?
|
| Tissue Donors | 2 | 2014 | 195 | 0.130 |
Why?
|
| Immunoglobulin G | 3 | 2014 | 481 | 0.130 |
Why?
|
| Mice, Transgenic | 4 | 2010 | 1033 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2011 | 447 | 0.120 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 10 | 0.120 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2014 | 41 | 0.120 |
Why?
|
| Butadienes | 1 | 2014 | 26 | 0.120 |
Why?
|
| HLA-C Antigens | 1 | 2014 | 8 | 0.120 |
Why?
|
| HLA-DQ Antigens | 1 | 2014 | 19 | 0.120 |
Why?
|
| Nitriles | 1 | 2014 | 68 | 0.120 |
Why?
|
| Sirtuin 1 | 1 | 2014 | 47 | 0.120 |
Why?
|
| Cytoplasm | 1 | 2014 | 155 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 39 | 0.120 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 149 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 247 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 151 | 0.110 |
Why?
|
| Megakaryocytes | 2 | 2010 | 18 | 0.110 |
Why?
|
| GATA1 Transcription Factor | 2 | 2010 | 19 | 0.110 |
Why?
|
| beta-Arrestins | 1 | 2013 | 80 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 376 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2004 | 447 | 0.100 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 3 | 2007 | 65 | 0.100 |
Why?
|
| Cell Line | 2 | 2014 | 1752 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2014 | 1200 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 511 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2009 | 146 | 0.100 |
Why?
|
| Transfection | 2 | 2010 | 782 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 209 | 0.090 |
Why?
|
| Platelet Activation | 1 | 2010 | 24 | 0.090 |
Why?
|
| HLA-DP Antigens | 1 | 2010 | 2 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2010 | 45 | 0.090 |
Why?
|
| Platelet Count | 1 | 2010 | 100 | 0.090 |
Why?
|
| Survival Rate | 3 | 2014 | 1056 | 0.090 |
Why?
|
| Homozygote | 1 | 2010 | 119 | 0.090 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 166 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 507 | 0.090 |
Why?
|
| Heterozygote | 1 | 2010 | 174 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2010 | 1692 | 0.090 |
Why?
|
| HeLa Cells | 1 | 2010 | 237 | 0.090 |
Why?
|
| Caco-2 Cells | 1 | 2009 | 37 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 40 | 0.090 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2009 | 26 | 0.090 |
Why?
|
| Thioredoxins | 1 | 2009 | 26 | 0.090 |
Why?
|
| Cell Division | 2 | 2008 | 541 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 282 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 322 | 0.090 |
Why?
|
| Cells, Cultured | 7 | 2009 | 2673 | 0.090 |
Why?
|
| Immunosorbent Techniques | 1 | 2009 | 18 | 0.080 |
Why?
|
| Female | 11 | 2020 | 38074 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 2791 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 34 | 0.080 |
Why?
|
| Male | 11 | 2020 | 37321 | 0.080 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2008 | 13 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 124 | 0.080 |
Why?
|
| Adipocytes | 1 | 2009 | 88 | 0.080 |
Why?
|
| Poly I-C | 1 | 2008 | 20 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2008 | 30 | 0.080 |
Why?
|
| Adoptive Transfer | 1 | 2008 | 100 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2010 | 483 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 181 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1553 | 0.070 |
Why?
|
| Gene Expression Regulation | 4 | 2008 | 1293 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2009 | 902 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 266 | 0.070 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 40 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 329 | 0.070 |
Why?
|
| Adult | 7 | 2020 | 21403 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 498 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2005 | 41 | 0.070 |
Why?
|
| Apoptosis | 1 | 2013 | 1641 | 0.070 |
Why?
|
| Antigens, Nuclear | 1 | 2005 | 24 | 0.060 |
Why?
|
| Thrombopoiesis | 1 | 2004 | 4 | 0.060 |
Why?
|
| Granulocytes | 1 | 2004 | 22 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 778 | 0.060 |
Why?
|
| Pregnancy | 1 | 2010 | 2334 | 0.060 |
Why?
|
| Autoantigens | 1 | 2005 | 91 | 0.060 |
Why?
|
| Middle Aged | 6 | 2020 | 21147 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2004 | 137 | 0.060 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 514 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 94 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 536 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 649 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 800 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 271 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2023 | 19 | 0.050 |
Why?
|
| Incidence | 3 | 2014 | 1603 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2021 | 7029 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 371 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 475 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2003 | 77 | 0.050 |
Why?
|
| Piperazines | 1 | 2023 | 206 | 0.050 |
Why?
|
| Clinical Audit | 1 | 2021 | 2 | 0.050 |
Why?
|
| Pyridines | 1 | 2023 | 261 | 0.050 |
Why?
|
| Prognosis | 1 | 2005 | 2093 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 629 | 0.050 |
Why?
|
| Skin | 1 | 2003 | 451 | 0.040 |
Why?
|
| Collagen | 1 | 2003 | 636 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7277 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2021 | 236 | 0.040 |
Why?
|
| Scleroderma, Systemic | 1 | 2003 | 446 | 0.040 |
Why?
|
| United States | 1 | 2011 | 7367 | 0.040 |
Why?
|
| Aged | 4 | 2020 | 14862 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 265 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 230 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2004 | 756 | 0.040 |
Why?
|
| Creatinine | 1 | 2018 | 243 | 0.040 |
Why?
|
| Infant | 2 | 2014 | 2891 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 3259 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 3705 | 0.040 |
Why?
|
| Adolescent | 3 | 2014 | 8912 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2014 | 3187 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.040 |
Why?
|
| Actins | 2 | 2009 | 249 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 2 | 2009 | 149 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1054 | 0.030 |
Why?
|
| Delayed Graft Function | 1 | 2016 | 39 | 0.030 |
Why?
|
| Risk Factors | 3 | 2016 | 5731 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2009 | 489 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2007 | 306 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 63 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 1038 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 238 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2008 | 532 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 320 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 365 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1070 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 5717 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 392 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 546 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 17 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1196 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.030 |
Why?
|
| Rabbits | 1 | 2014 | 509 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 4655 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.030 |
Why?
|
| Child | 2 | 2014 | 6405 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2014 | 109 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 737 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1420 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 540 | 0.030 |
Why?
|
| Registries | 1 | 2014 | 733 | 0.020 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2010 | 10 | 0.020 |
Why?
|
| HLA-DP beta-Chains | 1 | 2010 | 4 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2011 | 305 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 13 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2009 | 24 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2009 | 37 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 312 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 29 | 0.020 |
Why?
|
| Perilipin-1 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 30 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 63 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2009 | 49 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 144 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2009 | 117 | 0.020 |
Why?
|
| Desensitization, Immunologic | 1 | 2009 | 25 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 77 | 0.020 |
Why?
|
| Leptin | 1 | 2009 | 80 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2009 | 93 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 242 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 86 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2009 | 175 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2009 | 95 | 0.020 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2008 | 12 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 56 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 14 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1083 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2014 | 2455 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2008 | 84 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 202 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2008 | 89 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1447 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2008 | 168 | 0.020 |
Why?
|
| South Carolina | 1 | 2014 | 2752 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 261 | 0.020 |
Why?
|
| Vaccination | 1 | 2008 | 189 | 0.020 |
Why?
|
| Living Donors | 1 | 2009 | 160 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2007 | 161 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2008 | 201 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 397 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1174 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 362 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 597 | 0.020 |
Why?
|
| Diet | 1 | 2009 | 514 | 0.020 |
Why?
|
| Proteomics | 1 | 2007 | 246 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2005 | 54 | 0.020 |
Why?
|
| Integrin alpha2 | 1 | 2004 | 4 | 0.020 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2004 | 4 | 0.020 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 1 | 2004 | 9 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2004 | 7 | 0.020 |
Why?
|
| Chimera | 1 | 2004 | 33 | 0.020 |
Why?
|
| Receptors, Cytokine | 1 | 2004 | 19 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2004 | 118 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2004 | 58 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2004 | 144 | 0.010 |
Why?
|
| Proteinuria | 1 | 2004 | 136 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 772 | 0.010 |
Why?
|
| Chemokines | 1 | 2004 | 119 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 301 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 217 | 0.010 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2003 | 17 | 0.010 |
Why?
|
| Tuberculosis, Urogenital | 1 | 2003 | 2 | 0.010 |
Why?
|
| Egypt | 1 | 2003 | 5 | 0.010 |
Why?
|
| Rifampin | 1 | 2003 | 45 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2003 | 57 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 121 | 0.010 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2003 | 61 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 289 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 615 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 682 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2004 | 434 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 597 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2003 | 131 | 0.010 |
Why?
|
| Fibrosis | 1 | 2003 | 371 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 1030 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2003 | 193 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 384 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 626 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 866 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1330 | 0.010 |
Why?
|